The disruption of MDM2 regulation in neuroblastoma and the engagement of MYC family proteins in high-risk disease have led to the proposition that simultaneous targeting of both the MDM2 and MYCN might result in a synergistic increase in cytotoxicity in neuroblastoma models, providing a potential innovative therapeutic avenue. This evidence concerns the gene MDM2 and neuroblastoma.